{"symbol": "BIIB", "name": "Biogen", "next_earnings_utc": 1595417100, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 3436496120.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": 7.95854, "eps_up_revisions": 6, "eps_down_revisions": 21, "revenue_up_revisions": 2, "revenue_down_revisions": 21, "total_analysts": 35, "analysts_sell": 3, "analysts_buy": 8, "analysts_outperform": 4, "analysts_hold": 18, "analysts_underperform": 2, "webpage": "biogen.com", "year_founded": 1978, "street_address": "225 Binney Street", "city": "Cambridge", "state": "MA", "zipcode": "02142", "country": "United States", "phone_number": "617 679 2000", "short_description": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide.", "long_description": "Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 50113245075, "total_enterprise": 52608245075, "number_of_employees": 7400, "outstanding_shares": 163187486, "eps": 32.452663, "diluted_eps": 32.400198, "earnings_from_cont_operations": 5872300000, "gross_profit": 12614700000, "cash": 3860400000, "total_debt": 6365400000, "total_revenue": 14422400000, "cash_from_operations": 7086400000, "net_income": 5878800000, "ebitda": 7998900000, "year_low_stock_price": 215.78, "year_high_stock_price": 374.99, "seekingalpha_follower_count": 72128, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/BIIB.png"}